Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Magazine

Table: Brewing Drug Battle


Sales of rheumatoid arthritis drug Enbrel nearly doubled to $652 million last year, but supply shortfalls are opening doors for Immunex' rivals

JOHNSON & JOHNSON'S REMICADE

Like Enbrel, Remicade blocks the inflammatory agent TNF. With Immunex' drug in short supply, many physicians are prescribing Remicade, even though it must be taken with the harsh chemotherapy drug methotrexate.

AMGEN'S ANAKINRA

Expected to be approved by yearend, Anakinra blocks interleukin-1, another culprit in rheumatoid arthritis. Early data suggest it's not as effective as Enbrel--but with few good alternatives on the market, Amgen is likely to grab market share.

ABBOTT LABS' D2E7

Although this drug also blocks TNF, like Enbrel, its structure is closer to naturally occurring antibodies. That means patients could get the same benefit with lower doses--a prospect that enthralls drug analysts. Abbott should file for approval next year.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus